Another study revealed that abnormal elevation of serum FGF23 was associated with major adverse cardiovascular events in patients with acute coronary syndrome after percutaneous coronary intervention, and could be used as a serum indicator for early evaluation of adverse cardiovascular outcomes in patients with acute coronary syndrome [43]. Here, FGF23 is linked to acute coronary syndrome.